Sequence variations in HCV core-derived epitopes alter binding of KIR2DL3 to HLA-C∗03:04 and modulate NK cell function

Journal of Hepatology

Volumn 65, Issue 2, 2016, Pages 252-258

  Lunemann, Sebastian ^a   Martrus, Gloria ^a   Hölzemer, Angelique ^b   Chapel, Anais ^a   Ziegler, Maja ^a   Körner, Christian ^a   Garcia Beltran, Wilfredo ^d   Carrington, Mary ^d,e   Wedemeyer, Heiner ^c   Altfeld, Marcus ^a  

^a LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

HCV; HLA; KIR; NK

Indexed keywords

AMINO ACID; CORE PROTEIN; HEPATITIS C ANTIGEN; HLA C ANTIGEN; IMMUNOGLOBULIN G; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; NONSTRUCTURAL PROTEIN 3; PEPTIDE; EPITOPE;

AMINO ACID SEQUENCE; ANTIGEN BINDING; ANTIGEN PRESENTATION; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; GENOTYPE; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HLA SYSTEM; HUMAN; HUMAN CELL; INNATE IMMUNITY; MUTATION RATE; NATURAL KILLER CELL; NONHUMAN; NORMAL HUMAN; PEPTIDE SYNTHESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; STABLE TRANSFECTION; HEPATITIS C;

EPITOPES; HEPATITIS C; HLA-C ANTIGENS; HUMANS; KILLER CELLS, NATURAL; RECEPTORS, KIR2DL3;

EID: 84971656734     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.03.016     Document Type: Article

References (30)

1. [1] Jost, S., Altfeld, M., Control of human viral infections by natural killer cells. Annu Rev Immunol 31 (2013), 163–194.
2. [2] Vivier, E., Tomasello, E., Baratin, M., Walzer, T., Ugolini, S., Functions of natural killer cells. Nat Immunol 9 (2008), 503–510.
3. [3] Crome, S.Q., Lang, P.A., Lang, K.S., Ohashi, P.S., Natural killer cells regulate diverse T cell responses. Trends Immunol 34 (2013), 342–349.
4. [4] Moretta, A., The dialogue between human natural killer cells and dendritic cells. Curr Opin Immunol 17 (2005), 306–311.
5. [5] Long, E.O., Kim, H.S., Liu, D., Peterson, M.E., Rajagopalan, S., Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 31 (2013), 227–258.
6. [6] Lanier, L.L., Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9 (2008), 495–502.
7. [7] Parham, P., Moffett, A., Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol 13 (2013), 133–144.
8. [8] Jamil, K.M., Khakoo, S.I., KIR/HLA interactions and pathogen immunity. J Biomed Biotechnol, 2011, 2011, 298348.
9. [9] Long, E.O., Rajagopalan, S., HLA class I recognition by killer cell Ig-like receptors. Semin Immunol 12 (2000), 101–108.
10. [10] G. Alter, D. Heckerman, A. Schneidewind, L. Fadda, Kadie, C.M., Carlson, J.M., et al. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature 476 (2011), 96–100.
11. [11] Rehermann, B., Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 19 (2013), 859–868.
12. [12] Khakoo, S.I., Thio, C.L., Martin, M.P., Brooks, C.R., Gao, X., Astemborski, J., et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305 (2004), 872–874.
13. [13] Knapp, S., Warshow, U., Hegazy, D., Brackenbury, L., Guha, I.N., Fowell, A., et al. Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology 51 (2010), 1168–1175.
14. [14] Dring, M.M., Morrison, M.H., McSharry, B.P., Guinan, K.J., Hagan, R., et al., Irish HCV Research Consortium. Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc Natl Acad Sci U S A 108 (2011), 5736–5741.
15. [15] Sanjana, N.E., Shalem, O., Zhang, F., Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods 11 (2014), 783–784.
16. [16] N.H. van Teijlingen, A. Holzemer, Korner, C., Garcia-Beltran, W.F., Schafer, J.L., Fadda, L., et al. Sequence variations in HIV-1 p24 Gag-derived epitopes can alter binding of KIR2DL2 to HLA-C∗03:04 and modulate primary natural killer cell function. Aids 28 (2014), 1399–1408.
17. [17] Boyington, J.C., Motyka, S.A., Schuck, P., Brooks, A.G., Sun, P.D., Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature 405 (2000), 537–543.
18. [18] Messina, J.P., Humphreys, I., Flaxman, A., Brown, A., Cooke, G.S., Pybus, O.G., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
19. [19] Zeuzem, S., Asselah, T., Angus, P., Zarski, J.P., Larrey, D., Mullhaupt, B., et al. Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Antivir Ther 18 (2013), 1015–1019.
20. [20] Gane, E.J., Stedman, C.A., Hyland, R.H., Ding, X., Svarovskaia, E., Subramanian, G.M., et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 146 (2014), 736–743, e1.
21. [21] Wiegand, J., Deterding, K., Cornberg, M., Wedemeyer, H., Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha. J Antimicrob Chemother 62 (2008), 860–865.
22. [22] Ge, D., Fellay, J., Thompson, A.J., Simon, J.S., Shianna, K.V., Urban, T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461 (2009), 399–401.
23. [23] Donnelly, R.P., Kotenko, S.V., Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 30 (2010), 555–564.
24. [24] Parham, P., Immunology. NK cells lose their inhibition. Science 305 (2004), 786–787.
25. [25] Hill, A.B., Lee, S.P., Haurum, J.S., Murray, N., Yao, Q.Y., Rowe, M., et al. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised. J Exp Med 181 (1995), 2221–2228.
26. [26] Hansasuta, P., Dong, T., Thananchai, H., Weekes, M., Willberg, C., Aldemir, H., et al. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur J Immunol 34 (2004), 1673–1679.
27. [27] L. Fadda, C. Korner, Kumar, S., van Teijlingen, N.H., Piechocka-Trocha, A., Carrington, M., et al. HLA-Cw∗0102-restricted HIV-1 p24 epitope variants can modulate the binding of the inhibitory KIR2DL2 receptor and primary NK cell function. PLoS Pathog, 8, 2012, e1002805.
28. [28] Maenaka, K., Juji, T., Stuart, D.I., Jones, E.Y., Crystal structure of the human p58 killer cell inhibitory receptor (KIR2DL3) specific for HLA-Cw3-related MHC class I. Structure 7 (1999), 391–398.
29. [29] Rasmussen, M., Harndahl, M., Stryhn, A., Boucherma, R., Nielsen, L.L., Lemonnier, F.A., et al. Uncovering the peptide-binding specificities of HLA-C: a general strategy to determine the specificity of any MHC class I molecule. J Immunol 193 (2014), 4790–4802.
30. [30] Marquardt, N., Beziat, V., Nystrom, S., Hengst, J., Ivarsson, M.A., Kekalainen, E., et al. Cutting edge: identification and characterization of human intrahepatic CD49a+ NK cells. J Immunol 194 (2015), 2467–2471.